Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  OSTEOPOROSIS THERAPEUTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Osteoporosis Therapeutics in Millions of US$. The specific product segments analyzed are Bisphosphonates, ERT Drugs, SERMs, and Calcitonins. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region and product segment for the period of 2000 through 2015. The report profiles 52 companies including many key and niche players worldwide such as Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk, Organon, Procter & Gamble Pharmaceuticals, Inc., Sanofi-Aventis SA, Servier SA, Solvay Pharmaceuticals, Inc., Unigene Laboratories, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1229  PAGES:    278
PRICE:    $3950  DATE:       March 2008
COMPANIES:  52  MARKET DATA TABLES:   106
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  OSTEOPOROSIS THERAPEUTICS (Complete Report) Pages : 278   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation and Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Bisphosphonates.....I-3
Hormone Replacement Therapy/Estrogen Replacement Therapy.....I-3
  
   Estrogens.....I-4
Estrogens/Progesterones.....I-4
Calcitonins.....I-4
Selective Estrogen Receptor Modulators (SERMs).....I-4
Other Therapeutics.....I-4
  
II. EXECUTIVE SUMMARY59$2450
  1. Outlook.....II-12 $200  
   Regional Market Perspective.....II-1
United States.....II-1
Europe.....II-1
1$100
   Japan.....II-2
1$100
  2. Industry Overview.....II-38 $800  
   Osteoporosis Therapeutics: An Evolutionary Scan.....II-3
“A Sketch of the Present Industry Scenario”.....II-3
Facts & Figures: The Osteoporosis Primacy.....II-3
Snapshots.....II-3
1$100
   Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart).....II-4
Factors Influencing Demand.....II-4
Competitive Landscape.....II-4
1$300
   Table 2: Worldwide Osteoporosis Market (2006): Percentage Breakdown by Leading Players-Merck, Novartis, Eli Lilly, Procter & Gamble, Wyeth, and Others (includes corresponding Graph/Chart).....II-5

Table 3: Worldwide Osteoporosis Market (2005): Dollar Sales of Leading Osteoporosis Drugs-Fosamax, Actonel, Evista, Miacalcic, and Forteo (In US$ Thousands) (includes corresponding Graph/Chart).....II-5

Table 4: Leading Osteoporosis Therapies and its Cost per Day.....II-5
1$300
   Market Trends and Issues.....II-6
Can New Treatments Beat the Gold Standard?.....II-6
Oral Calcitonin Likely to Emerge as Wonder Drug.....II-6
1$100
   New Bisphosphonates Challenge Established Brands.....II-7
Side Effects of HRT Fuel Natural Alternatives Sales.....II-7
Bone Formation Drugs Augur New Prospects.....II-7
1$100
   A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics.....II-81$100
   Estrogen Replacement Therapy: Will Dosing Make a Difference?.....II-9
Is Prevention Always Better Than Cure?.....II-9
Peptide-Based Osteoporosis Therapy Gaining Ground.....II-9
Polymorphism- A Potent Diagnostic Marker.....II-9
Bisphosphonates – The Other Side.....II-9
1$100
   Efficacy of Evista Under the Scanner.....II-10
1$100
  3. Major Therapeutic Classes: A Global Perspective.....II-112 $200  
   ERT Drugs.....II-11
Ups and Downs in the ERT Market.....II-11
Outlook.....II-11
Bisphosphonates.....II-11
The leading Therapeutic Market......II-11
1$100
   SERMS .....II-12
Market Overview.....II-12
Calcitonins.....II-12
Market Overview.....II-12
1$100
  4. Product Overview.....II-1311 $800  
   The “Silent Thief”.....II-13
An Introduction to Bone Physiology.....II-13
How Osteoporosis Steps In.....II-13
1$100
   Osteoporosis: Major Types.....II-14
Primary Osteoporosis.....II-14
Secondary Osteoporosis.....II-14
1$100
   Osteoporosis - The Aftermath.....II-15
Prevention: The Only Better Way Out.....II-15
Osteoporosis Therapies: A Cursory Glance.....II-15
Nondrug Therapy.....II-15
1$100
   Drug Therapy.....II-16
Major Osteoporosis Therapeutic Classes: A Brief Review.....II-16
Bisphosphonates.....II-16
Classification of Bisphosphonates.....II-16
Etidronate.....II-16
1$100
   Alendronate.....II-17
Risedronate.....II-17
Calcitonin: A Relatively Safer Therapeutic.....II-17
What It Is.....II-17
What It Does.....II-17
Major Types.....II-17
Salmon Calcitonin.....II-17
1$100
   SERM: A Breakthrough.....II-18
Raloxifene: The First SERM.....II-18
SERMs: The Positive Angle.....II-18
SERMs: The Negative Side.....II-18
Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding
  Therapeutic.....II-18
1$100
   ERT: The Positive Side.....II-19
The Negative Angle to ERT.....II-19
Tereparatide: The First Anabolic Agent.....II-19
Composition.....II-19
Forteo: A Leading Brand.....II-19
1$100
   Major Therapeutic Classes at a Glance.....II-201$100
   Osteoporosis Therapeutics: A Peek into the Major Brands.....II-211$100
   New Drugs/Drug Classes in Pipeline.....II-22
SERMs.....II-22
Bisphosphonates.....II-22
Zoledronic Acid:.....II-22
Pamidronate:.....II-22
Reclast.....II-22
Calcitonin.....II-22
Parathyroid Hormone (PTH).....II-22
1$100
   Denosumab (AMG-162).....II-23
Combination Therapy.....II-23
1$100
  5. Major Clinical Trials/Findings.....II-244 $400  
   End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure.....II-24
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics.....II-24
1$100
   Radius Initiates Phase II Trials for BA058.....II-25
Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon
  Calcitonin.....II-25
Medivir Initiates First Human Trials for MIV-701.....II-25
1$100
   Osteologix Begins Phase II Trial of NB S101.....II-26
Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™.....II-26
1$100
   Acceleron Initiates Phase I Clinical Trial of ACE-011.....II-27
Positive Results from Reclast Clinical Trials.....II-27
1$100
  6. Product Introductions/Approvals.....II-287 $700  
   P&G Receives FDA Approval for New Dosage of Actonel.....II-28
Takeda Introduces Benet® for Osteoporosis Treatment.....II-28
Labtec Obtains Approval to Market Hormone Replacement Patch in Europe.....II-28
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA.....II-28
Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval.....II-28
1$100
   Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug.....II-29
Roche and GlaxoSmithKline Introduce Bonviva.....II-29
1$100
   GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval.....II-30
Nycomed’s Preotact Recommended for Approval in Europe.....II-30
Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male Osteoporosis.....II-30
Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray.....II-30
1$100
   Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets.....II-31
GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland.....II-31
Roche’s Once-a-month Bisphosphonate Gets FDA Nod.....II-31
Actonel with Calcium® Obtains FDA Approval.....II-31
1$100
   FDA Approves Unigene’s Nasal Calcitonin.....II-32
Novavax’s ESTRASORB® Clears FDA Hurdle.....II-32
Menostar™ Secures FDA Approval.....II-32
Bonviva Gains European Commission Approval.....II-32
Schering Introduces New Hormone Therapy Products.....II-32
Eli Lilly Launches Evista in Japan and China.....II-32
1$100
   Proteolos Bags EU Approval.....II-33
Forcaltonin® Secures European Approval.....II-33
Ministry of Health Labor and Welfare Approves P&G’s Actonel®.....II-33
Eli Lilly’s Osteoporosis Drug Obtains US Approval.....II-33
Vivelle Dot 0.025 ERT Patch from Novogyne.....II-33
Novartis Rolls Out Estradot.....II-33
1$100
   Pfizer Launches FemHRT.....II-34
Ligand Unveils LGD2226.....II-34
1$100
  7. Recent Industry Activity.....II-359 $900  
   Schering-Plough Acquires Organon BioSciences.....II-35
Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline.....II-35
Alethia and Emerillon Collaborate on Osteoporosis Therapies.....II-35
Ipsen Enters into Co-marketing Agreement with MSD.....II-35
1$100
   Unigene Enters into Agreement with Novartis.....II-36
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs.....II-36
Procter & Gamble Terminates Nasal Spray Collaboration with Nastech
  Pharmaceutical.....II-36
Pharming Group Acquires DNage.....II-36
1$100
   Amgen Acquires Abgenix.....II-37
P&G Licenses Osteoporosis Nasal Spray Rights from Nastech.....II-37
Eli Lilly to Close Basingstoke Plant.....II-37
1$100
   Galapagos Acquires Drug Discovery Platform of Discovery Partners.....II-38
Duravest Acquires Bio-Magnetic Therapy.....II-38
Galapagos Acquires ProStrakan’s ProSkelia.....II-38
Roche Inks a Marketing Agreement with Elder Pharma.....II-38
1$100
   Chugai and Taisho Sign a Joint Development and Marketing Agreement.....II-39
Theragenex Signs a Licensing Agreement with Zylera.....II-39
Radius Acquires Licensing Agreement for Eisai’s SERMs.....II-39
Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation.....II-39
1$100
   Radius Acquires Exclusive Rights to Karo Bio’s SARMS.....II-40
Unigene Enters into Agreement with Tzamal Bio.....II-40
Galapagos Acquires Inpharmatica.....II-40
Bio-Rad Acquires Provalis Medical Diagnostics Operations.....II-40
1$100
   Daiichi Sankyo to Market Evista in Europe.....II-41
Biocon Acquires Nobex.....II-41
Radius and Ipsen Enters into Licensing Agreement.....II-41
1$100
   Novartis Acquires Hexal AG.....II-42
Nippon Chemiphar Signs Agreement with Velcura Therapeutics.....II-42
Biopotential Capital Acquires Osta Biopharma.....II-42
Dnage Commences DNA Research Programme for Osteoporosis Therapeutics.....II-42
Nastech Initiates Phase I Study of PTH 1-34.....II-42
1$100
   SEQUENOM Collaborates with P&G Pharmaceuticals.....II-43
Novartis Extends Alliance with Emisphere.....II-43
Eli Lilly Markets Forteo in Europe.....II-43
Avesthagen Co-develops Osteoporosis Drug with CCBR.....II-43
Nastech Signs Agreement with Par Pharmaceutical, Inc.....II-43
Unigene and Novartis in a Licensing and Manufacturing Agreement.....II-43
1$100
  8. Developments in the Recent Past.....II-442 $200  
   Wyeth Ties Up with Tanox and Galapagos.....II-44
Galapagos and P&G Collaborate to Develop Osteoporosis Drugs.....II-44
Unigene Grants License to Faran.....II-44
Genome Collaborates with Amgen.....II-44
Unigene Joins Hands with Shijiazhuang.....II-44
Unigene, GSK Signs License Collaboration.....II-44
1$100
   Unigene and Upsher-Smith in a Licensing Agreement.....II-45
Celgene and Novartis Embark on Joint Research for SERMs.....II-45
Roche, GSK Signs Global Agreement.....II-45
Novogyne Procures CombiPatch™ from Aventis.....II-45
1$100
  9. Focus on Select Global Players.....II-464 $400  
   Eli Lilly and Company (US).....II-46
F.Hoffmann-La Roche Ltd (Switzerland).....II-46
Merck & Co., Inc. (US).....II-46
Novartis AG (Switzerland).....II-46
Novo Nordisk A/S (Denmark).....II-46
1$100
   Organon .....II-47
Procter & Gamble Pharmaceuticals Inc. (US).....II-47
Sanofi-Aventis SA (France).....II-47
1$100
   Servier SA (France).....II-48
Solvay Pharmaceuticals Inc. (US).....II-48
Unigene Laboratories, Inc. (US).....II-48
Wyeth (US).....II-48
2$200
  10. Global Market Perspective.....II-50   
   Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-501$300
   Table 6: World Long-Term Projections for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-51

Table 7: World 10-Year Perspective for Osteoporosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-51
1$300
   Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-52

Table 9: World Long-Term Projections for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-52
1$300
   Table 10: World 10-Year Perspective for Bisphosphonates by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-531$300
   Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-54

Table 12: World Long-Term Projections for ERT Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-54
1$300
   Table 13: World 10-Year Perspective for ERT Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-551$300
   Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-56

Table 15: World Long-Term Projections for SERMs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-56
1$300
   Table 16: World 10-Year Perspective for SERMs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-571$300
   Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-58

Table 18: World Long-Term Projections for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-58
1$300
   Table 19: World 10-Year Perspective for Calcitonins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....II-591$300
III. MARKET33$2150
  1. United States.....III-119 $1050  
   A. Market Analysis.....III-1
Industry Overview.....III-1
Outlook.....III-1
Osteoporosis in the US: An Insight.....III-1
Osteoporosis – An Underserved Market?.....III-1
1$75
   Statistical Review.....III-2
Table 20: Incidence of Osteoporosis in the US (2004) (includes corresponding Graph/Chart).....III-2
1$150
   Table 21: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart).....III-31$150
   Table 22: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart).....III-4
Osteoporosis Prescription Market.....III-4
Table 23: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs- Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart).....III-4
Competitive Scenario.....III-4
1$150
   Table 24: Leading Players in the US Osteoporosis Market (2004) – Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi-Aventis and Others (includes corresponding Graph/Chart).....III-5
Competitive Review by Segment.....III-5
Bisphosphonates.....III-5
Table 25: Leading Players in the US Bisphosphonates Market (2004) – Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi-Aventis.....III-5
1$150
   Table 26: Leading Players in the US Bisphosphonates Market (2008) – Market Share by Value Sales for Merck, Procter & Gamble/ Sanofi-Aventis, Novartis and Roche/GSK (includes corresponding Graph/Chart).....III-6
SERMs.....III-6
Calcitonins.....III-6
Patent Expiry Catalog of Major Osteoporosis Drugs.....III-6
1$150
   Product Launches/Approvals.....III-73$225
   Strategic Corporate Developments.....III-105$275
   Select US Players.....III-153$225
   B. Market Analytics.....III-18
Table 27: US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-18
1$150
   Table 28: US Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-19

Table 29: US 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-19
1$150
  2. Japan.....III-204 $325  
   A. Market Analysis.....III-20
Product Launches/Approvals.....III-20
1$75
   Strategic Corporate Development.....III-211$75
   B. Market Analytics.....III-22
Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22

Table 31: Japanese Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-22
1$150
   Table 32: Japanese 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-23
1$150
  3. Europe.....III-2410 $750  
   A. Market Analysis.....III-24
Outlook.....III-24
Forsteo: The First Anabolic Agent in Europe.....III-24
European Regulatory Restricts HRT.....III-24
1$75
   Calcitonins Embraces New Label.....III-25
Table 33: European Market for Osteoporosis Therapeutics (2005): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart).....III-25
Product Launches/Approvals.....III-25
2$300
   Strategic Corporate Developments.....III-272$150
   Select European Players.....III-291$75
   B. Market Analytics.....III-30
Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-30
1$150
   Table 35: European Long-Term Projections for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-31

Table 36: European 10-Year Perspective for Osteoporosis Therapeutics by Geographic Regions – Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-31
1$150
   Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-32

Table 38: European Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-32
1$150
   Table 39: European 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-33
1$150
  3a. France.....III-343 $275  
   A. Market Analysis.....III-34
Strategic Corporate Developments.....III-34
1$75
   B. Market Analytics.....III-35
Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-35

Table 41: French Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-35
1$150
   Table 42: French 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-36
1$150
  3b. Germany.....III-372 $225  
   Market Analysis.....III-37
Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-37
1$150
   Table 44: German Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-38

Table 45: German 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-38
1$150
  3c. The United Kingdom.....III-394 $325  
   A. Market Analysis.....III-39
Osteoporosis Population Forecast in the UK.....III-39
Osteoporosis Population in the UK: 2004 –2009E.....III-39
1$75
   Product Launches.....III-40
Strategic Corporate Developments.....III-40
1$75
   B. Market Analytics.....III-41
Table 46: UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-41
1$150
   Table 47: UK Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-42

Table 48: UK 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-42
1$150
  3d. Italy.....III-432 $225  
   Market Analysis.....III-43
Table 49: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-43
1$150
   Table 50: Italian Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-44

Table 51: Italian 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-44
1$150
  3e. Spain.....III-453 $250  
   A. Market Analysis.....III-45
Strategic Corporate Development.....III-45
1$75
   B. Market Analytics.....III-46
Table 52: Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-46

Table 53: Spanish Long-Term Projections for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-46
1$150
   Table 54: Spanish 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-47
1$150
  3f. Rest of Europe.....III-485 $375  
   A. Market Analysis.....III-48
Outlook.....III-48
Romania.....III-48
Strategic Corporate Developments.....III-48
1$75
   Select Players in Rest of Europe.....III-492$150
   B. Market Analytics.....III-51
Table 55: Rest of Europe Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-51

Table 56: Rest of Europe Long-Term Projections for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-51
1$150
   Table 57: Rest of Europe 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-52
1$150
  4. Rest of World.....III-535 $600  
   A. Market Analysis.....III-53
Outlook.....III-53
Prevalence of Osteoporosis in Various Region-At a Glance.....III-53
Korea.....III-53
Table 58: Leading Brands in the Korean Osteoporosis Therapeutics Market (2005): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart).....III-53
1$150
   China.....III-54
Schering Pharmaceutical Limited (China) – A Major Player.....III-54
Product Launch.....III-54
Strategic Corporate Developments.....III-54
2$150
   B. Market Analytics.....III-56
Table 59: Rest of World Market for Osteoporosis Therapeutics - Recent Past, Current & Future Analysis by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-56

Table 60: Rest of World Long-Term Projections for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
   Table 61: Rest of World 10-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins for Years 2000, 2007 & 2010 (includes corresponding Graph/Chart).....III-571$150
IV. COMPETITIVE LANDSCAPE149$995
  
Total Companies Profiled: 52 (including Divisions/Subsidiaries - 66 )

Region/Country                 Players

The United States                  29
Canada                              4
Japan                               6
Europe                             20
     France                         3
     Germany                        3
     The United Kingdom             3
     Italy                          2
     Spain                          1
     Rest of Europe                 8
Asia-Pacific (Excluding Japan)      5
Middle East                         2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.